LivingGLP1
Study S001930

EBIRIOS - Exenatide and Basal Insulins Use in the Real Setting: an Italian Observational Study in Patients With Type 2 Diabetes and Secondary Failure of Oral Antihyperglycemic Treatment

ClinicalTrials.gov record

Registration

Registration
NCT01060059
Study type
OBSERVATIONAL
Status
COMPLETED
Enrollment
888
Start
2010-04
Primary completion
2012-05
Lead sponsor
AstraZeneca
Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG:exenatide; DRUG:basal insulin
Results posted
TRUE

Registered primary outcomes

  • Percentage of Patients Who Achieved Glycemic Target of HbA1c ≤ 7.0% With Minimal Weight Gain (≤ 1 Kg) at Month 12. [Baseline, Month 12]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.